Literature DB >> 11557632

Amylin infusion into rat nucleus accumbens potently depresses motor activity and ingestive behavior.

B A Baldo1, A E Kelley.   

Abstract

Amylin, a calcitonin gene-related peptide-like peptide coreleased with insulin, exerts anorexic effects on central administration. Because previous studies revealed dense amylin binding in the nucleus accumbens (Acb), we investigated the behavioral effects of amylin infusions (10, 30, and 100 ng/side) into Acb subregions. Intra-Acb shell amylin infusions decreased ambulation, rearing, feeding, and drinking in either food-deprived rats or water-deprived rats; motor activity was affected more potently than ingestive behavior. Moreover, intra-Acb shell amylin reduced motor activity in nondeprived rats tested in the absence of food or water, indicating that the expression of amylin's effects is independent of drive or proximal incentives. Intra-Acb core amylin infusions in water-deprived rats also decreased ambulation and water intake, although anterior Acb placements were associated with smaller motor effects, regardless of Acb subregion. In contrast to amylin's effects, intra-Acb shell infusions of orexin-A (50, 100, and 500 ng/side) had no effects on motor activity, feeding, or drinking. Hence the Acb may be a target for behavioral regulation by satiety-related peptides like amylin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557632     DOI: 10.1152/ajpregu.2001.281.4.R1232

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  25 in total

1.  The subfornical organ: a central target for circulating feeding signals.

Authors:  Katherine J Pulman; W Mark Fry; G Trevor Cottrell; Alastair V Ferguson
Journal:  J Neurosci       Date:  2006-02-15       Impact factor: 6.167

2.  Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys.

Authors:  Nicholas T Bello; Matthew H Kemm; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-05-14       Impact factor: 3.619

3.  Amylin receptor signaling in the nucleus accumbens negatively modulates μ-opioid-driven feeding.

Authors:  Sarah K Baisley; Brian A Baldo
Journal:  Neuropsychopharmacology       Date:  2014-06-24       Impact factor: 7.853

Review 4.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 5.  Amylin-mediated control of glycemia, energy balance, and cognition.

Authors:  Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2016-02-27

Review 6.  Neuropeptides controlling energy balance: orexins and neuromedins.

Authors:  Joshua P Nixon; Catherine M Kotz; Colleen M Novak; Charles J Billington; Jennifer A Teske
Journal:  Handb Exp Pharmacol       Date:  2012

7.  Brain microvascular injury and white matter disease provoked by diabetes-associated hyperamylinemia.

Authors:  Han Ly; Nirmal Verma; Fengen Wu; Miao Liu; Kathryn E Saatman; Peter T Nelson; John T Slevin; Larry B Goldstein; Geert Jan Biessels; Florin Despa
Journal:  Ann Neurol       Date:  2017-07-29       Impact factor: 10.422

8.  Amylin suppresses acetic acid-induced visceral pain and spinal c-fos expression in the mouse.

Authors:  X Huang; J Yang; J K Chang; N J Dun
Journal:  Neuroscience       Date:  2009-12-01       Impact factor: 3.590

9.  Sweetened-fat intake sensitizes gamma-aminobutyric acid-mediated feeding responses elicited from the nucleus accumbens shell.

Authors:  Sarah Newman; Lindsay Pascal; Ken Sadeghian; Brian A Baldo
Journal:  Biol Psychiatry       Date:  2013-01-08       Impact factor: 13.382

10.  Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake.

Authors:  Elizabeth G Mietlicki-Baase; Laura E Rupprecht; Diana R Olivos; Derek J Zimmer; Mark D Alter; R Christopher Pierce; Heath D Schmidt; Matthew R Hayes
Journal:  Neuropsychopharmacology       Date:  2013-03-08       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.